To assess prognostic roles of KRAS mutations in colorectal cancer, BRAF mutation status must be controlled because BRAF-mutated cancers are associated with poorer prognosis than BRAFwild-type cases, and almost all BRAF mutants are present among KRAS-wild-type tumors.
INTRODUCTION
Colorectal cancer develops through a multistep carcinogenic process with an accumulation of epigenetic and genetic changes, including KRAS mutation. Approximately 40% of colorectal cancers harbor KRAS mutations, and 90% of those mutations occur in codons 12 and 13 (1) (2) (3) . In contrast to the widely-accepted predictive role of KRAS mutation in identifying resistance to anti-EGFR therapy (3-8) the prognostic role of KRAS mutation in colorectal cancer remains uncertain (9) (10) (11) (12) (13) (14) . Recently, the differential biological effect of various KRAS mutations in colorectal cancer was brought to light by data from De Rook et al. (15) , showing that the c.38G>A (p.G13D) mutation was associated with benefit from cetuximab whereas KRAS codon 12 mutations were associated with resistance to cetuximab among chemotherapy-refractory colorectal cancer patients. A search of the literature to-date reveals that several studies (16) (17) (18) (19) (20) (21) have compared the prognostic roles of KRAS codon 12 mutations with those of codon 13.
Nonetheless, there is a lack of agreement as to the prognostic difference between KRAS codon 12 and codon 13 mutations in colorectal cancer ( Table 1) .
Of note, little attention has been given to the confounding effect of BRAF mutation on the relationship between KRAS mutation and clinical outcome in colorectal cancer. Almost all BRAF-mutated colorectal cancers are present within the group of KRAS-wild-type cancers.
Compared to BRAF-wild-type cases, BRAF mutation has been associated with poorer prognosis in several studies (10, 11, 19, (21) (22) (23) , hence, it is impossible to clarify the exact prognostic roles of KRAS mutations in colorectal cancer without controlling for BRAF mutation. Importantly, none of the previous large studies (with a sample size of N≥300) (16, 17, 19, 20) controlled for the potential confounding effect of BRAF mutation, while only one smaller study (N=229) been sent follow-up questionnaires to identify newly diagnosed cancers in themselves and their first degree relatives. We collected paraffin-embedded tissue blocks from hospitals where patients underwent colorectal cancer resections (29) . We collected diagnostic biopsy specimens for rectal cancer patients who received preoperative treatment, in order to avoid artifacts or bias introduced by treatment. Hematoxylin and eosin (HE) stained tissue sections from all colorectal cancer cases were reviewed by a pathologist (S.O.) unaware of other data. A subset of cases (N=172) were reviewed by another pathologist (T.M.), and the concordance between the two observers was 0.96 (κ =0.72; P<0.0001), indicating substantial agreement. The tumor differentiation was categorized as well-moderate vs. poor (>50% vs. ≤50% gland formation).
Initially, 1261 colorectal cancer cases diagnosed up to 2006 were included based on the availability of tumor tissue, sequencing data for both KRAS and BRAF, and survival data ( Table   2 ). Treatment data were not available in this study. In our current study, BRAF-mutated cancers (N=181) were excluded in order to assess the prognostic role of various KRAS mutations in a pool of BRAF-wild-type cases. Tumors harboring mutations in both codons 12 and 13 (N=5) of KRAS were excluded, resulting in a final total of 1075 BRAF-wild-type cases as our survival analysis study base (Figure 1 (31) and PIK3CA (exons 9 and 20) as previously described (32) . Pyrosequencing technology has been shown to reliably detect KRAS mutation with 100% analytic sensitivity and specificity, even when the proportion of mutant alleles is as low as 10% (30) . We dissected tumor-only areas, maintaining neoplastic cellularity of at least 30%. Assuming no laboratory error, both positive and negative predictive values are estimated to be 100%. MSI analysis was performed using 10 microsatellite markers (D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67 and D18S487) (2). MSI-high was defined as instability in ≥30% of the markers, and MSI-low/microsatellite stability (MSS) as instability in 0-29% of the markers.
Methylation analyses for CpG islands and LINE-1
Using validated bisulfite DNA treatment and real-time PCR (MethyLight), we quantified Author Manuscript Published OnlineFirst on July 2, 2012; DOI: 10.1158/1078-0432.CCR-11-3210 8 absence (0/8) of methylated promoters according to the previously established criteria (2) . In order to accurately quantify differences in relatively high LINE-1 methylation levels, we used Pyrosequencing as previously described (34, 35) .
Statistical analysis
All statistical analyses were performed by using SAS (Version 9.2, SAS Institute, Cary, NC). All P-values were two-sided. For our main hypothesis on the prognostic significance of KRAS codon 12 mutation among BRAF-wild-type cases, a P-value for significance was set at P=0.05. When we performed multiple hypothesis testing on specific KRAS mutations (the seven most common mutations), the P-value for significance was adjusted by Bonferroni correction to P=0.007 (=0.05/7). When we performed multiple hypothesis testing on associations or interactions between KRAS mutations (codon 12 or 13) and other covariates, a P-value for significance was adjusted by Bonferroni correction to P=0.0021 (=0.05/24). For categorical data, the chi-square test was performed. To compare mean age and mean LINE-1 methylation level, the t-test assuming equal variances was performed.
The Kaplan-Meier method was used to assess survival time distribution, and log-rank test was used. For analyses of colorectal cancer-specific mortality, deaths as a result of other causes were censored. To control for confounding, we used multivariate Cox proportional hazards regression models. A multivariate model initially included sex, age at diagnosis (continuous), IIIB, IIIC, IV or unknown) was used as a stratifying variable using the "strata" option in the SAS "proc phreg" command. A backward stepwise elimination was performed with P=0.20, as a threshold to avoid overfitting. For cases with missing information in any of the categorical covariates [tumor location (0.5%), tumor differentiation (0.7%), MSI (2.0%), CIMP (7.2%) and PIK3CA (8.5%)], we included those cases in the majority category of a given covariate to avoid overfitting. We confirmed that excluding cases with missing information in any of the covariates did not substantially alter results (data not shown). The proportionality of hazards assumption was satisfied by evaluating time-dependent variables, which were the cross products of the KRAS indicator variables (codon 12 mutant and codon 13 mutant; vs. KRAS-wild-type/BRAF-wildtype) and survival time (all P values >0.14 for colorectal cancer-specific mortality and overall mortality). We also tested for potential interaction between KRAS mutation status and each of the other covariates (including sex, age at diagnosis, family history of colorectal cancer, tumor location, disease stage, tumor differentiation, MSI, CIMP, PIK3CA, and LINE-1 methylation). 
RESULTS

KRAS mutation status in colorectal cancer
Among 1261 patients with incident colorectal cancer in the two U.S. nationwide prospective cohort studies, we detected KRAS codon 12 and/or 13 mutations in 451 (36%) patients; 335 in codon 12 only, 110 in codon 13 only, and six in both codons 12 and 13. For 
KRAS mutation status and patient survival in BRAF-wild-type cases
When assessing the prognostic effect of KRAS mutation, it is necessary to consider a confounding effect of BRAF mutation, because BRAF mutation is associated with poorer Table 3 ]. In contrast, compared to KRASwild-type/BRAF-wild-type cases, patients with KRAS codon 13 mutations did not experience any significant reduction in survival ( Table 3) .
Among the seven most common KRAS codon 12 and 13 mutations, c.35G>T (p.G12V; N=93) was associated with significantly higher colorectal cancer-specific mortality (log-rank
Research. Table 2 ).
In order to assess the impact of confounding by BRAF mutation, we repeated the above survival analyses including BRAF-mutated cases, most of which were included in the KRAS wild-type group. A total case number for this additional analysis was 1255, including 180 BRAF-mutated cases. Compared to KRAS-wild-type cases, KRAS codon 12 mutations were not significantly associated with colorectal cancer-specific mortality in multivariate analysis and the HR effect estimate was substantially attenuated (Supplementary Table 3 ). Among the seven most common KRAS codon 12 and 13 mutations, compared to KRAS-wild-type cases, the HR effect estimates for c.34G>C (p.G12R) and c.35G>T (p.G12V) mutations were considerably attenuated.
KRAS mutation status and mortality in strata of other variables
As exploratory analyses, we examined the prognostic association of KRAS codon 12 and PIK3CA, and LINE-1 methylation. We did not observe considerable or significant modifying effect by any of these variables on KRAS codon 12 or 13 mutation [all P interaction >0.02; given multiple hypothesis testing, a statistical significance level was adjusted to P interaction =0.0021)].
DISCUSSION
We conducted this study to assess whether KRAS codon 12 mutated tumors represent a more aggressive subtype as compared to either KRAS codon 13 mutated tumors or KRAS-wildtype tumors, within a group of BRAF-wild-type tumors (i.e., controlling for BRAF mutation status). We showed that KRAS codon 12 mutations, but not codon 13 mutations, were associated with significantly higher mortality compared to KRAS-wild-type/BRAF-wild-type cases. In particular, c.35G>T (p.G12V) mutation was associated with the highest colorectal cancerspecific mortality (multivariate HR=2.00, 95% CI, 1.38-2.90, P=0.0003). Our data are consistent with previous laboratory studies (24, 25) suggesting that the presence of a mutation in KRAS codon 12 confers substantially greater oncogenic potential as compared to codon 13 mutation. Our data are also consistent with a recent study that showed that KRAS codon 12 mutations, but not codon 13 mutations, conferred resistance to cetuximab in advanced colorectal cancer (15) .
Detection of somatic molecular aberrations and tumor molecular classification are increasingly important in colorectal cancer (36) (37) (38) (39) . We used Pyrosequencing technology, which has been shown to be more sensitive than Sanger sequencing in detecting KRAS mutations in
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paraffin-embedded archival tissue (30, 40, 41) . Pyrosequencing is a sensitive sequencing assay and can reliably detect mutant alleles of low abundance (10% mutant) among wild-type alleles, which is a common situation in solid tumors (30, 40, 41) .
To the best of our knowledge based on the literature search in Pubmed, this is the first study to address the prognostic difference between KRAS codon 12 and codon 13 mutations in more than 1000 of BRAF-wild-type colorectal cancers (i.e., controlling for BRAF mutation status). Although several previous studies have distinguished between the prognostic associations of KRAS mutations in codon 12 and codon 13 ( Table 1 resistant to ARHGAP-mediated GTPase activation, leading to elevated cellular levels of RAS-GTP (42). Guerrero and colleagues (24) found that KRAS codon 12 mutation, by altering the threshold for induction of apoptosis, confers a more aggressive tumor phenotype than codon 13 mutation. This suggests that codon 12 mutation results in greater resistance to ARHGAPmediated GTPase activation than codon 13 mutation (24). Consequently, codon 12 mutated RAS theoretically remains in an active GTP-bound state longer than codon 13 mutated or wild- Limitations of the current study include the lack of data on cancer treatment.
Chemotherapeutic and surgical interventions have a significant impact on disease progression in metastatic colorectal cancer. We cannot exclude the possibility that there may have been an imbalance in the use of therapeutic interventions between subgroups. KRAS mutation status has recently become an important biomarker when selecting chemotherapeutic agents for colorectal cancer therapy (6) (7) (8) 48) . Given that we could not control for use of EGFR inhibitors, such as cetuximab and panitumumab, bias may have arisen through selective use of these agents within the study group. Nonetheless, it seems unlikely that chemotherapy use or regimen differed substantially by tumor KRAS mutation status, since a vast majority of cases were diagnosed in 1990's to early 2000's, before 2006, when KRAS mutation emerged as a predictive biomarker in stage IV colorectal cancer. In addition, our molecular data were not available for patients or clinicians for treatment decision making. Another weakness of this study is the absence of data on cancer recurrence, and, as a result, disease-free survival was not an available outcome measurement in these cohorts. Because the median survival of metastatic colorectal cancer patients was 10 to 12 months during the time period of this study (49) , we believe that colorectal cancer-specific survival is a reasonably robust surrogate for cancer-specific outcomes. In fact, disease-free survival has been shown to be highly correlated with overall survival (50) .
Strengths of the current study include the use of data from two U.S. nationwide prospective cohort studies. Information on disease staging, family history of cancer, and other clinicopathologic and tumor molecular data was prospectively integrated into the molecular pathological epidemiology database (26) (27) (28) . Cohort participants who were diagnosed with colorectal cancer were presented and treated at hospitals throughout the United States, and thus more representative colorectal cancers in the general U.S. population than are patients in single or few academic medical centers. Finally, by virtue of our molecular pathological epidemiology (26-28) database, we assessed the effects of KRAS codon 12 and 13 mutations independent of various clinicopathologic features and other critical molecular events such as BRAF and PIK3CA mutations, MSI, CIMP and LINE-1 hypomethylation, all of which have been associated with colorectal cancer prognosis (2, 34).
In conclusion, our study of over 1000 colorectal cancers has shown that KRAS codon 12 mutation (in particular, c.35G>T, p.G12V), but not codon 13 mutation, is associated with worse 
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Many 1413 The multivariate Cox regression model included the same set of covariates selected as in Table 3 . A P-value for significance was adjusted for multiple hypothesis testing to P=0.05/7=0.007. Thus, a P-value between 0.05 and 0.007 should be regarded as of borderline significance. CI, confidence interval; HR, hazard ratio; NS, not significant. 
